Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Drugmakers have been under scrutiny since Mylan's EpiPen price hike, but government involvement in controlling costs is not necessarily the answer, Wells Fargo Securities analyst David Maris said Thursday.
"I don't think that having government run that process is really the right way, because it's a Trojan horse for price controls. Once they start controlling a little bit of price, then the temptation is to control all of price, and if you do that, you really get fewer drugs invented," he said in an interview with CNBC's "Power Lunch" from the Wells Fargo Healthcare Conference in Boston.
Instead, Maris thinks the pharmaceutical industry will likely follow Allergan's example of policing its prices.
The Botox-maker has said it will raise prices no more than once a year and keep the hikes to no more than low-to-mid-single-digit percentages.
Maris called the move brilliant, and said it reflects the current corporate culture.
"Everyone understands that drug companies should make a little bit more each year; that their costs go up. Their people have to get paid more. Science costs more to do. But if we could limit maybe the outliers," he said.
Mylan has come under fire for boosting the price of its anti-allergy injection device to more than $600 — up from about $100 in 2008. The company has since said it will launch the first generic version of the drug at half the price.